Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Active Biotech ABOSTO:ACTI +0.98%26 Equity-to-Asset is 0.81 as of Mar. 2026, which is 37% above its 10-year median of 0.59. GuruFocus rates OSTO:ACTI with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Active Biotech AB ranks better than 67.16% on this metric.
Active Biotech AB (OSTO:ACTI) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Active Biotech AB Equity-to-Asset Related Terms
Active Biotech AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Active Biotech AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ACTI vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Active Biotech AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Active Biotech AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Active Biotech AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Active Biotech AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Active Biotech AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Active Biotech AB (OSTO:ACTI) has a Equity-to-Asset of 0.81 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Active Biotech AB and its competitors. This is 37% above median its historical median of 0.59. Over the past decade, Active Biotech AB's Equity-to-Asset has ranged from 0.09 to 0.89. According to the industry distribution chart, Active Biotech AB ranks #465 out of 1416 companies in the Biotechnology industry, placing it in the top 32.8%.
Is Active Biotech AB's Equity-to-Asset too high?
Active Biotech AB's current Equity-to-Asset of 0.81 is 37% above median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.89. The Biotechnology industry median Equity-to-Asset is 0.68. Active Biotech AB's value of 0.81 is 19.1% above this industry median. Based on the distribution chart, Active Biotech AB ranks #465 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Active Biotech AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Active Biotech AB ranks #465 out of 1416 companies for Equity-to-Asset. This puts Active Biotech AB in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Active Biotech AB's value of 0.81 is 19.1% above this benchmark. Historically, Active Biotech AB's own Equity-to-Asset has ranged from 0.09 to 0.89 over the past decade. While the company's 10-year median is 0.59 vs. the industry median of 0.68, Active Biotech AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Active Biotech AB's current Equity-to-Asset of 0.81 is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Active Biotech AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Active Biotech AB's current Equity-to-Asset is 0.81, which is 37% above median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Active Biotech AB (OSTO:ACTI) has a current Equity-to-Asset of 0.81. The current Equity-to-Asset is 0.81, which is 37% above median its 10-year median of 0.59 and 19.1% above the Biotechnology industry median of 0.68. Active Biotech AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Active Biotech AB (OSTO:ACTI), the current Equity-to-Asset is 0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
26GF Score
Get the complete analysis for OSTO:ACTI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACTI has been successfully added to your 
